WHAT IS CMT?
A disease of the peripheral nerves that control muscles (unlike the muscular dystrophies, which affect the muscles themselves). [1,2]
Before molecular biology and genetic testing, CMT disorders were broadly classified into Type 1 (with abnormally low nerve conduction velocities, suggesting demyelination) and Type 2 (with normal nerve conduction velocities, suggesting axonal or neuronal degeneration).
Found in both genders and in all races and ethnic groups, it is the most commonly inherited peripheral neuropathy, affecting 2.8 million people worldwide.
This rare, inherited, slowly progressive neuropathies that came to be known as Charcot-Marie-Tooth (CMT) disorders were described independently in 1886 by Charcot and Marie in France and by Tooth in the UK.
Onset can occur at any age but is most frequent in the first and second decades of life [1,2].
MOBILIZATION TO REDUCE DIAGNOSTIC ERROR
APP CMT & ME
An international observational study to collect Real-World Evidence (RWE) data from people living with CMT will be launched progressively in Europe by the end of 2018. The objective of the study is to better understand the impact of the disease on patients’ daily life: the burden of CMT, its natural history and treatment, and medical, social and pharmacoeconomic effects.
Participants will be able to download and use the CMT&Me App on their smartphones or tablets (Android or iOS) in the comfort of their own home or on the go, and data will be collected in real-time. They will be able to fill out background and quality of life questionnaires, record their symptoms in a diary and access the knowledge section which contains medical and practical information about the condition.
For regular update on the study and the CMT&Me app, please visit ecmtf.org.
SILENCE IS NO LONGER POSSIBLE!
ECMTF / Fondation Universitaire
11 Rue D’Egmont – B-1000 Brussels – Belgium
President: Daniel Tanesse (France)
Vice President: Filippo Genovese (Italy)